Published in J Infect Dis on May 01, 1998
Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med (2006) 4.50
Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis (2011) 1.71
A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates. J Virol (2007) 1.50
Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS One (2010) 1.08
Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years. Hum Vaccin Immunother (2013) 0.86
The contribution of systemic and pulmonary immune effectors to vaccine-induced protection from H5N1 influenza virus infection. J Virol (2012) 0.83
New vaccine development. BMJ (2002) 0.83
Role of lymphotoxin and homeostatic chemokines in the development and function of local lymphoid tissues in the respiratory tract. Inmunologia (2007) 0.80
Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) in Adults. Clin Vaccine Immunol (2016) 0.75
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med (1998) 6.75
Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA (1999) 3.69
Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA (1999) 3.53
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr (2000) 3.53
Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA (2000) 3.50
Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med (1989) 3.16
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis (2000) 2.90
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis (2000) 2.90
Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci U S A (1999) 2.41
Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology (1997) 2.37
T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol (1998) 2.31
Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol (2005) 2.28
Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis (1989) 2.21
Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A (2001) 2.20
Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis (1982) 2.17
Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis (2000) 2.13
Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol (1992) 2.12
Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections. J Clin Microbiol (1987) 2.06
Serologic analysis of first-episode nonprimary genital herpes simplex virus infection. Presence of type 2 antibody in acute serum samples. Am J Med (1984) 2.05
Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J Infect Dis (1999) 2.02
Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J Clin Microbiol (1996) 1.98
Enzyme-linked immunosorbent assay for measurement of serological response to respiratory syncytial virus infection. Infect Immun (1978) 1.96
Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2. Virology (1995) 1.86
Effect of meals on rifampicin absorption. Lancet (1974) 1.84
Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis (1995) 1.83
High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr (1994) 1.83
Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV. Virology (1998) 1.82
Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics (1996) 1.77
Pulmonary involvement in human T-cell lymphotropic virus type-I uveitis: T-lymphocytosis and high proviral DNA load in bronchoalveolar lavage fluid. Eur Respir J (1993) 1.77
Influenza virus infections in infants. Pediatr Infect Dis J (1997) 1.75
Experimental respiratory syncytial virus infection of four species of primates. J Med Virol (1977) 1.74
Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J (1999) 1.73
Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics (2001) 1.70
Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis (1987) 1.68
Human rotavirus studies in volunteers: determination of infectious dose and serological response to infection. J Infect Dis (1986) 1.68
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis (1993) 1.67
Dual respiratory virus infections. Clin Infect Dis (1997) 1.67
Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis (1993) 1.62
Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect Immun (1982) 1.61
Respiratory syncytial virus epidemics: variable dominance of subgroups A and B strains among children, 1981-1986. J Infect Dis (1988) 1.58
Lower respiratory tract infections due to adenovirus in hospitalized Korean children: epidemiology, clinical features, and prognosis. Clin Infect Dis (2001) 1.58
Allergic reactions to workplace allergens. JAMA (1997) 1.57
The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection. Sex Transm Infect (2006) 1.56
Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke (2001) 1.56
Evaluation of a possible association of urban air toxics and asthma. Environ Health Perspect (1995) 1.52
Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res (1992) 1.51
Palmitoylation of the influenza A virus M2 protein. Virology (1990) 1.51
Further consideration of the clonal nature of Salmonella typhi: evaluation of molecular and clinical characteristics of strains from Indonesia and Peru. J Clin Microbiol (1992) 1.50
Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob Agents Chemother (2000) 1.49
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis (1998) 1.47
Maternal immunization against viral disease. Vaccine (1998) 1.47
Evaluation of occupational asthma from airborne egg protein exposure in multiple settings. Chest (1990) 1.45
Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy (1999) 1.45
Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother (1991) 1.43
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med (1991) 1.43
Evaluation of five temperature-sensitive mutants of respiratory syncytial virus in primates: I. Viral shedding, immunologic response, and associated illness. J Med Virol (1978) 1.42
Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis (1998) 1.40
House dust (1-3)-beta-D-glucan and wheezing in infants. Allergy (2007) 1.40
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. JAMA (1995) 1.40
Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr (1992) 1.38
Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine (2000) 1.38
Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract. Virology (1995) 1.36
Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am J Epidemiol (1991) 1.36
Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun (1994) 1.35
Guinea pig model for antibiotic transport across gastric mucosa: inhibitory tissue concentrations of clindamycin against Helicobacter pylori (Campylobacter pylori) following two separate dose regimens. Antimicrob Agents Chemother (1990) 1.35
Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis (1994) 1.34
Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis (1998) 1.33
Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant (1995) 1.32
The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. J Infect Dis (1999) 1.32
Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults. J Clin Microbiol (1990) 1.31
Experimental respiratory syncytial virus pneumonia in cebus monkeys. J Med Virol (1978) 1.30
Temperature-sensitive mutants of influenza A virus. XIV. Production and evaluation of influenza A/Georgia/74-ts-1[E] recombinant viruses in human adults. J Infect Dis (1977) 1.29
Pulmonary and immunologic evaluation of foundry workers exposed to methylene diphenyldiisocyanate (MDI). J Allergy Clin Immunol (1988) 1.29
Formation and persistence of novel benzo(a)pyrene adducts in rat lung, liver, and peripheral blood lymphocyte DNA. Cancer Res (1990) 1.28
Cold-recombinant influenza A/California/10/78 (H1N1) virus vaccine (CR-37) in seronegative children: infectivity and efficacy against investigational challenge. J Infect Dis (1984) 1.28
Mediastinal and supraclavicular lymphadenitis and pneumonitis due to Chlamydia trachomatis serovars L1 and L2. N Engl J Med (1984) 1.25
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J Infect Dis (1992) 1.25
Rapid detection of parainfluenza virus type 3 RNA in respiratory specimens: use of reverse transcription-PCR-enzyme immunoassay. J Clin Microbiol (1994) 1.25
Nosocomial influenza B virus infection in the elderly. Ann Intern Med (1982) 1.25
Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol (1991) 1.24
Acceptability of human papillomavirus self testing in female adolescents. Sex Transm Infect (2005) 1.24
A rapid test for infectious and inflammatory enteritis. Arch Intern Med (1995) 1.23
Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis (2001) 1.23
Serological diagnosis of influenza B virus infection: comparison of an enzyme-linked immunosorbent assay and the hemagglutination inhibition test. J Clin Microbiol (1982) 1.23
Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents. Clin Infect Dis (1997) 1.22
Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis (1993) 1.21
Further characterization of the complementation group B temperature-sensitive mutant of respiratory syncytial virus. J Virol (1977) 1.21
Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics (1993) 1.21
Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin. J Infect Dis (1996) 1.21